The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …

Understanding the mechanism for antibody neutralization of SARS-CoV-2 is critical for the
development of effective therapeutics and vaccines. We recently isolated a large number of …

SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier
and caused widespread disease in the past two decades. The development of a universal …

Abstract The coronavirus disease 2019 (COVID-19) pandemic presents an urgent health
crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain …

The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …

Understanding how potent neutralizing antibodies (NAbs) inhibit SARS-CoV-2 is critical for
effective therapeutic development. We previously described BD-368-2, a SARS-CoV-2 NAb …

Neutralizing antibodies (nAbs) to SARS-CoV-2 hold powerful potentials for clinical
interventions against COVID-19 disease. However, their common genetic and biologic …

The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health …

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …

SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed.
Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led …